Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
130.1 USD | -0.12% | +2.19% | +19.52% |
09/05 | Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma | MT |
09/05 | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
Sales 2024 * | 64.11B 5,351B | Sales 2025 * | 68.6B 5,726B | Capitalization | 330B 27,534B |
---|---|---|---|---|---|
Net income 2024 * | 19.51B 1,629B | Net income 2025 * | 22.27B 1,859B | EV / Sales 2024 * | 5.44 x |
Net Debt 2024 * | 18.91B 1,579B | Net Debt 2025 * | 7.6B 635B | EV / Sales 2025 * | 4.92 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.6
x | Employees | 71,000 |
Yield 2024 * |
2.38% | Yield 2025 * |
2.51% | Free-Float | 70.77% |
Latest transcript on Merck & Co., Inc.
1 day | +0.09% | ||
1 week | +1.54% | ||
Current month | +0.78% | ||
1 month | +2.78% | ||
3 months | +3.81% | ||
6 months | +27.20% | ||
Current year | +19.46% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01/14/01 |
Director of Finance/CFO | 55 | 01/90/01 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27/07/27 |
Pamela Craig
BRD | Director/Board Member | 67 | 01/15/01 |
Inge Thulin
BRD | Director/Board Member | 69 | 01/18/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 0 M€ | +11.39% | - | |
5.61% | 0 M€ | +7.69% | - |
Date | Price | Change | Volume |
---|---|---|---|
11/24/11 | 130.1 | -0.12% | 3 825 112 |
09/24/09 | 130.2 | +0.52% | 9,216,740 |
08/24/08 | 129.6 | -0.64% | 6,659,121 |
07/24/07 | 130.4 | +2.20% | 6,682,316 |
06/24/06 | 127.6 | +0.05% | 6,551,962 |
Delayed Quote Nyse, May 10, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.46% | 330B | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+3.50% | 283B | |
+16.98% | 239B | |
+8.04% | 204B | |
-7.98% | 198B | |
+8.62% | 168B | |
+4.37% | 125B |
- Stock Market
- Equities
- MRK Stock